Double Repositioning: Veterinary Antiparasitic to Human Anticancer
Tania Sultana1, Umair Jan1, Jeong Ik Lee1,2
1Regenerative Medicine Laboratory, Center for Stem Cell Research, Department of Biomedical Science and Technology, Institute of Biomedical Science and Technology, Konkuk University, Seoul 05029, Korea.
International Journal of Molecular Sciences
|April 23, 2022
Summary
Repurposing veterinary antiparasitic drugs offers a promising avenue for novel anticancer therapies. These repurposed drugs show significant anti-tumor activity and potential for improved cancer patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Veterinary Medicine
Background:
- Drug repositioning is increasingly vital in anticancer drug discovery.
- Veterinary antiparasitic drugs are emerging as potential anticancer agents.
- Double repositioning involves repurposing drugs for different species and diseases simultaneously.
Purpose of the Study:
- To review veterinary antiparasitic drugs as potential anticancer agents for human use.
- To summarize experimental, preclinical, and clinical evidence for these repurposed drugs.
- To explore novel treatment options for cancer patients.
Main Methods:
- Literature review of veterinary antiparasitic drugs with anticancer activity.
- Analysis of mechanisms of action, including inhibition of mitochondrial respiration and cellular stress responses.
- Compilation of data from experimental, preclinical, and clinical trials.
Main Results:
- Veterinary antiparasitics like benzimidazole carbamates and halogenated salicylanilides demonstrate significant anti-tumor activities.
- These agents act via diverse mechanisms, targeting oncogenic pathways and cellular stress.
- Evidence from various trials supports their potential in human cancer treatment.
Conclusions:
- Veterinary antiparasitic drugs represent a viable source for novel anticancer drug repositioning.
- These repurposed agents offer potential for improved quality of life and outcomes for cancer patients.
- Further research and clinical trials are warranted to fully explore their therapeutic potential.
Keywords:
antiparasiticbenzimidazole carbamatescancer therapydrug repurposinghalogenated salicylanilidesMore Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11.1K
04:48Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
7.5K
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
487
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
487
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
344
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
344